title: Agonist or levodopa for Parkinson disease? Ultimately, it doesn't matter; neither is good enough.
authors.forename: Erwin B
authors.initials: EB
authors.lastname: Montgomery
mesh_terms: D001971:Bromocriptine / Q000008:administration & dosage / Q000009:adverse effects; D015259:Dopamine Agents / Q000008:administration & dosage / Q000009:adverse effects; D018491:Dopamine Agonists / Q000008:administration & dosage* / Q000009:adverse effects; D004409:Dyskinesia, Drug-Induced / Q000453:epidemiology; D005500:Follow-Up Studies; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects; D007980:Levodopa / Q000008:administration & dosage* / Q000009:adverse effects*; D010300:Parkinson Disease / Q000188:drug therapy*; D010818:Practice Patterns, Physicians'; D015995:Prevalence; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D013995:Time; D016896:Treatment Outcome
chemical_list: D015259:Dopamine Agents; D018491:Dopamine Agonists; D007211:Indoles; C046649:ropinirole; D001971:Bromocriptine; D007980:Levodopa